INMB

News

globenewswire.comINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trialglobenewswire.comJun 2

globenewswire.comINmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platformglobenewswire.comMay 15

globenewswire.comINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Diseaseglobenewswire.comMay 14

globenewswire.comINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Pointglobenewswire.comMay 13

Trade INMB

About INmune Bio, Inc.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

CEO: David J. Moss
IPO Date: Feb 4, 2019

Market Data

Open: $1.32
High: $1.45
Low: $1.32
Volume: 439.9K
Avg Volume: 396K
52W High: $11.64
52W Low: $1.09

Valuation

Market Cap: $39M
Enterprise Value: $19M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-24M
Revenue: $50k
Net Income: $-46M
Cash: $25M
Debt: $1.0M

Events

EarningsAug 6

EPS est. -0.1875